Over the last 7 days, the United States market has remained flat, though it is up 17% over the past year, with earnings expected to grow by 17% per annum over the next few years. Penny stocks may be a throwback term, but they represent opportunities that are far from outdated. Typically associated with smaller or newer companies, these stocks can offer growth potential at lower price points when backed by strong balance sheets and solid fundamentals.

Here's a peek at a few of the choices from the screener.

Lisata Therapeutics (LSTA)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing therapies for solid tumors and other diseases, with a market cap of $15.68 million.

Operations: Lisata Therapeutics, Inc. has not reported any revenue segments.

Market Cap: $15.68M

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company with a market cap of US$15.68 million, remains pre-revenue and unprofitable. Despite reducing losses by 15.9% annually over the past five years, it faces significant challenges including high volatility and less than one year of cash runway. The company is exploring strategic alternatives to enhance shareholder value while having recently downsized its workforce by 72%. A merger agreement with Kuva Labs was cancelled due to financing issues, leaving Lisata's future uncertain as it navigates potential acquisitions or asset sales amidst ongoing financial constraints and strategic evaluations.

Commerce.com (CMRC)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Commerce.com, Inc. operates an artificial intelligence-driven commerce ecosystem across various regions including the United States, Europe, the Middle East, Africa, and the Asia Pacific, with a market cap of $0.19 billion.

Operations: The company generates $346.90 million in revenue from its Internet Information Providers segment.

Market Cap: $193.06M

Commerce.com, Inc. operates within the AI-driven commerce ecosystem with a market cap of US$0.19 billion and revenue of US$346.90 million from its Internet Information Providers segment. Despite being unprofitable with a negative return on equity, it has reduced losses by 33.4% annually over five years and maintains sufficient cash runway for over three years due to positive free cash flow growth. Recently, the company lowered its 2026 revenue guidance and reported Q2 sales of US$84.51 million with a net income turnaround to US$1.1 million from a loss last year, indicating potential operational improvements amidst strategic partnerships enhancing eCommerce capabilities.

Vera Bradley (VRA)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Vera Bradley, Inc., along with its subsidiaries, designs and manufactures women's handbags, luggage and travel items, fashion and home accessories, and gifts in the United States with a market cap of $91 million.

Operations: The company's revenue is primarily generated through its Direct segment, accounting for $229.56 million, and the Indirect segment, which contributes $44.14 million.

Market Cap: $91M

Vera Bradley, Inc., with a market cap of US$91 million, recently expanded its retail presence through a partnership with Nordstrom, offering its products in all full-line locations and online. Despite being unprofitable and experiencing declining earnings over the past five years, Vera Bradley maintains a debt-free status and has sufficient cash runway for over three years. The company's short-term assets of US$111.5 million comfortably cover both short- and long-term liabilities. Although its management team is relatively new, the company continues to innovate product lines to attract a broader consumer base amidst ongoing financial challenges.

Taking Advantage

• Click through to start exploring the rest of the 308 US Penny Stocks now.
• Seeking Other Investments? Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.